4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial

4basebio Signs Clinical Supply Agreement

to

Support Phase II

Clinical Trial

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate

Multi-year, seven-figure revenue stream reflecting increased commercial momentum

CAMBRIDGE, UK –

20 May

2026

– 4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has signed a Clinical Supply Agreement with a leading cancer immunotherapy innovator (“the Client”) to provide GMP-grade opDNA® starting material for its latest clinical programme.

Under the terms of the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client’s immunotherapy candidate for an upcoming Phase II clinical trial. The agreement is expected to provide an approximate seven-figure revenue stream over the next 12 months, reflecting 4basebio’s unique capability to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines.

By leveraging 4basebio’s enzymatic, cell-free manufacturing process, the

Client will enhance

the safety of its therapeutic product by fully eliminating microbial contamination and the inclusion of antibiotic resistance genes, helping to

accelerate its development timelines from sequence to clinic

.

Amy Walker, Chief Executive Officer at 4basebio, added

: “This partnership demonstrates how our proprietary DNA technology platform can help clients overcome complex manufacturing hurdles and bring safer and effective therapies to patients. We continue to see growing interest in our DNA molecules across the genetic medicine space and are delighted to support our partners through their clinical trials.”

.